(Reuters) – GSK’s vaccine candidate to treat gonorrhea, a sexually transmitted infection, has been granted fast-track designation by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Tuesday.
The experimental Neisseria gonorrhoeae vaccine is currently mid-stage and aims to demonstrate vaccine efficacy in healthy adults who are at high risk of infection, the company said in a statement.
The FDA’s “Fast Track” designation is intended to facilitate the development and expedite the review of potentially important new drugs and vaccines to treat or prevent serious conditions with unmet medical needs.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)